4C-TFM, also known as TFM-Ariadne or 4C-DOTFM, as well as 4-trifluoromethyl-2,5-dimethoxy-α-ethylphenethylamine, is a serotonin 5-HT2 receptor agonist of the phenethylamine, phenylisobutylamine, and 4C families related to Ariadne (4C-D). It is a close analogue of the psychedelic drugs 2C-TFM and DOTFM, with 2C-TFM having no substitution at the α carbon, DOTFM having an α-methyl group, and 4C-TFM having an α-ethyl group. The drug is a potent agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It shows similar efficacy as an agonist of these receptors as Ariadne, but shows about 6.4-fold higher potency as a serotonin 5-HT2A receptor agonist in comparison. Like Ariadne, 4C-TFM produces an attenuated head-twitch response relative to the psychedelic drug DOPR, with a similar maximal response as Ariadne. The chemical synthesis of 4C-TFM has been described. 4C-TFM was first described in the scientific literature by Michael Cunningham and colleagues in 2023.
See also 4C (psychedelics)
References
External links 4C-TFM - Isomer Design